Drug Profile
Research programme: T-cell receptor cancer immunotherapies - Medigene AG/Phio Pharmaceuticals
Alternative Names: TCR immunotherapies - Medigene/Phio PharmaceuticalsLatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator MediGene AG
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Cancer in Germany (Parenteral)
- 25 Feb 2019 European Patent Office intends to grant an European Patent for T cell receptor (TCR) building block library
- 19 Nov 2018 RXi Pharmaceuticals is now called Phio Pharmaceuticals